MeCure Industries Plc has opened a new funding window through the issuance of a N10 billion, 269-day Series 6 Commercial Paper, the latest tranche under its N40 billion Commercial Paper Programme.
The company announced that the offer carries a discount rate of 18.19 percent and an effective annual yield of 21 percent, positioning it as a competitive short-term instrument for institutional and high-net-worth investors seeking strong returns within a defined period.
According to the issuance timetable, the offer opened on December 9, 2025, and will close on December 12, 2025. Investors are required to subscribe with a minimum commitment of N5 million, while additional investments can be made in multiples of N1,000.
The settlement date is set for December 14, 2025, after which the commercial paper will run its full tenor until September 26, 2026. At maturity, investors will be paid the full redemption value.
Industry analysts note that the issuance reflects MeCure’s broader strategy to manage working capital efficiently and deepen its presence in Nigeria’s fixed-income market. The strong yield profile is also expected to attract significant participation amid sustained demand for short-term securities within the corporate debt space.
The company is one of Nigeria’s leading pharmaceutical and diagnostics providers, and its recurring participation in the debt market continues to signal active expansion and operational strengthening across its business segments.
